Cerus Corporation

Cerus Corporation is a biomedical company dedicated to safeguarding the global blood supply through pathogen reduction technologies. Founded in 1991 in Concord, California, and publicly listed since 1997, Cerus develops and supplies the INTERCEPT Blood System—a proprietary technology that inactivates pathogens (HIV, bacteria, viruses, parasites) in blood components by targeting their nucleic acids. The INTERCEPT Blood System is approved by FDA and CE mark for platelets and plasma treatment and is used by blood centers and hospitals worldwide. In the U.S., Cerus also markets INTERCEPT Fibrinogen Complex (Pathogen Reduced Cryoprecipitated Fibrinogen Complex) for treating bleeding and hemorrhage associated with fibrinogen deficiency. The company's INTERCEPT red blood cell system is in late-stage clinical development in the U.S. and under regulatory review in Europe. Cerus serves as a critical partner to blood centers and hospitals, enabling safe transfusion practices and reducing infection risk in healthcare systems globally.